Boehringer Ingelheim, which holds a 16.4% share of Hikma along with voting rights, is ready to exit the company altogether as Hikma decides to buy back £295m worth of shares. Hikma has invited new investors, expressing confidence in its future plans.
Hikma Pharmaceuticals has announced that it will buy back approximately £295m ($367m) worth of shares from Boehringer Ingelheim, representing the firm’s full holding in Hikma.
Funding the buy-back with cash and available facilities, Hikma said that the move demonstrated the board’s confidence in Hikma’s future...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
